查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1981739

多体学市场：按产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Multiomics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年多体学市场价值 26.2 亿美元，预计到 2026 年将成长至 29.3 亿美元，复合年增长率为 12.50%，到 2032 年将达到 59.8 亿美元。

主要市场统计数据
基准年 2025 26.2亿美元
预计年份：2026年 29.3亿美元
预测年份 2032 59.8亿美元
复合年增长率 (%) 12.50%

我们将多组体学定位为一个综合领域，它结合了技术进步、资料管治和转化重点，并将其策略性地引入以指导投资指南。

多组体学正在重塑机构建构和解答生物学问题的方式，本文将该领域置于技术、资料科学和转化应用目标的交汇点。过去十年，研究人员已摒弃了孤立的检测方法，转而采用整合基因组学、转录组学、蛋白质组学、代谢体学、脂类组学学和表观基因数据的策略。这揭示了在单体学方法中常常被忽略的机制。因此，在实验设计中，样本完整性、统一的元元资料和分析可重复性如今同等重要，以确保跨组体学方法的可比性。

重大变革正在重塑多组体学的应用，这是由技术融合、法规演变以及对检验的转化工作流程的需求所驱动的。

多组体学领域正经历着一场变革性的转型，其驱动力来自技术融合、不断变化的临床需求以及新兴资料科学能力。定序能力和准确性的提升、先进的质谱平台以及自动化的样本製备流程正在降低技术门槛，并扩大可行的研究设计范围。同时，机器学习和网路生物学领域的演算法创新正在开闢新的解读层面，使研究人员能够从复杂的多维资料集中推导出机制性假设。

本分析探讨了关税压力对供应链的影响如何推动体学学价值链的在地化、供应商多元化和弹性筹资策略。

2025年美国关税环境对多组体学生态系统内的供应链韧性、筹资策略和成本结构提出了实际挑战。对实验室设备、试剂或进口组件征收关税可能会增加总体成本，迫使製造商和买家评估替代供应商、实现关键生产过程本地化或重新谈判供应商合约。为此，许多机构正在重新评估其平台投资的总体拥有成本 (TCO)，并优先考虑那些供应链透明且製造地分散的供应商。

全面的细分洞察揭示了技术选择、体学方法、产品类型、应用和最终用户需求如何决定采用路径和价值创造。

关键的细分洞察揭示了技术选择、科学研究重点和终端用户需求之间的交集，从而塑造了技术应用路径和价值提案。基于技术，市场涵盖质谱、微阵列、qPCR 和定序，其中定序又细分为次世代定序和桑格定序。这些技术的组合决定了处理能力、灵敏度以及研究人员可应用的下游分析类型。基于体学，该领域延伸至表观基因、基因组学、脂类组学、代谢体学、蛋白质组学和转录组学。每个体学层面都具有其独特的生物学背景，并带来与样品製备、动态范围和数据整合相关的固有分析挑战。

可操作的区域见解解释了美洲、欧洲、中东和非洲以及亚太地区的趋势如何影响多组体学的技术采用、监管和伙伴关係策略。

区域趋势对多组体学领域的技术应用、监管协调和伙伴关係策略产生了深远影响。在美洲，研究活动、创业投资资金以及强大的生物技术丛集网路正在推动先进定序和质谱平台的快速应用。然而，复杂的报销机制和法规结构要求制定有针对性的检验策略。同时，该地区的产学研合作以及合约研究组织（CRO）正在促进转化研究流程的构建，从而加速概念验证（PoC）研究和早期临床应用。

主要企业洞察强调了平台整合、检验能力和服务差异化如何决定多体学领域中每个参与者的竞争优势。

多组体学领域的竞争格局归根结底在于能否提供可靠、检验的端到端解决方案，这些方案需结合高性能仪器、可重复使用的耗材和可扩展的分析能力。主要企业透过投资平台互通性、在临床或农业环境中验证其效用，以及透过伙伴关係将其价值提案扩展到下游应用，从而脱颖而出。策略併购和伙伴关係活动不断将专业能力（例如小众样品製备技术和先进资讯学）与更广泛的平台提供者相结合，旨在提供全面的服务。

为行业领导者提供可操作的建议，以增强平台互通性、供应链韧性、监管合规性和服务主导的商业化策略。

行业领导者可以透过优先考虑韧性和以客户为中心，同时使策略行动与技术和监管现实相符，从而加速价值创造。首先，投资可互通平台和开放资料标准可以减少整合摩擦，并增强解决方案对拥有异质基础设施的终端用户的吸引力。其次，扩大本地生产和建立区域伙伴关係可以降低关税和供应链风险，同时缩短关键耗材和试剂的交付时间。

为了确保分析的有效性和相关性，我们采用了严谨的混合方法调查方法，将对专家的直接访谈与第二手资料。

本调查方法透过整合一手和二手研究，确保分析的严谨性、可重复性和有效性。一手研究包括对领域专家、实验室主任和服务供应商进行结构化访谈，以了解实际操作、检验流程和采购因素。这些定性资讯与技术文献、同行评审研究和供应商文件进行交叉比对，以检验有关平台功能、检测局限性和分析工作流程的说法。

决定性的整合凸显了对检验的工作流程、可互通的平台以及强大的商业化策略的必要性，以实现多体学的影响。

总之，多组体学代表着生命科学领域的一个策略转折点，它整合了分子谱分析、先进仪器和复杂分析方法，从而能够提供更深入的生物学见解并产生转化应用的影响。该领域的成熟需要技术创新，同时辅以稳健的资料管治、标准化的工作流程和具有商业性可行性的服务模式，以降低应用门槛。政策变化和贸易趋势凸显了供应链韧性和区域灵活性的重要性，因此，在地化和伙伴关係策略对于长期业务永续营运至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 多组体学市场：依产品类型划分

  • 消耗品
  • 装置
  • 软体和服务
    • 服务
      • 数据分析
      • 样品製备
    • 软体

第九章：多组体学市场：依技术划分

  • 质谱分析
  • 微阵列
  • qPCR
  • 定序
    • 次世代定序
    • 桑格定序

第十章：多组体学市场：依应用划分

  • 农业和食品检验
  • 生物标记发现
  • 临床诊断
  • 药物发现与开发
  • 个人化医疗

第十一章：多组体学市场：依最终用户划分

  • 学术研究机构
  • 合约研究机构
  • 医院和诊断检测实验室
  • 製药和生物技术公司

第十二章 多组体学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：多组体学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 多组体学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国多组体学市场

第十六章：中国多体学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-CF699CF41428

The Multiomics Market was valued at USD 2.62 billion in 2025 and is projected to grow to USD 2.93 billion in 2026, with a CAGR of 12.50%, reaching USD 5.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.62 billion
Estimated Year [2026] USD 2.93 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 12.50%

A strategic introduction framing multiomics as an integrative discipline that fuses technological advances, data governance, and translational priorities to guide investment

Multiomics is reshaping how organizations ask and answer biological questions, and this introduction situates the field at the intersection of technology, data science, and translational ambition. Over the past decade, practitioners have moved beyond siloed assays to integrated strategies that layer genomics, transcriptomics, proteomics, metabolomics, lipidomics, and epigenomics data to reveal mechanistic insights that single-omic approaches often miss. Consequently, experimental design now places equal emphasis on sample integrity, harmonized metadata, and analytical reproducibility to support cross-omic comparability.

As multiomics applications expand from discovery biology into clinical diagnostics, drug development, and personalized medicine, stakeholders must reconcile differing regulatory expectations, data governance frameworks, and validation requirements. This evolution elevates the importance of standardized protocols and interoperable data formats, while simultaneously driving demand for analytics platforms that translate heterogenous datasets into clinically meaningful signatures. Moreover, advances in sequencing chemistry, mass spectrometry sensitivity, and computational tools have reduced technical barriers, encouraging cross-disciplinary collaboration among wet-lab scientists, bioinformaticians, and clinicians.

Taken together, these dynamics position multiomics as both a scientific enabler and a strategic lever. Institutions that align organizational processes, invest in reproducible workflows, and foster data-driven cultures are best placed to capture the translational value of integrated molecular profiling. The remainder of this executive summary unpacks the transformative shifts, policy impacts, segmentation insights, and regional considerations that will shape adoption and competitive differentiation.

Key transformative shifts reshaping multiomics adoption driven by convergent technologies, regulatory evolution, and demand for validated translational workflows

The landscape of multiomics is undergoing transformative shifts driven by converging technological advances, evolving clinical priorities, and emergent data science capabilities. Improvements in sequencing throughput and accuracy, enhanced mass spectrometry platforms, and automated sample preparation workflows are lowering technical friction and expanding the range of feasible study designs. Simultaneously, algorithmic innovations in machine learning and network biology are unlocking new interpretive layers, enabling researchers to extract mechanistic hypotheses from complex, multi-dimensional datasets.

At the same time, regulatory and ethical considerations are reshaping how organizations approach data stewardship. Greater emphasis on provenance, auditability, and cross-institutional data sharing is accelerating investments in secure platforms and federated analysis models that preserve patient privacy while enabling large-scale integrative studies. Clinical demand for actionable biomarkers, coupled with heightened expectations for analytical validation and clinical utility, is pushing developers to prioritize reproducibility and transparent performance metrics.

Operationally, there is a clear move toward end-to-end solutions that combine consumables, instruments, and services into validated workflows. This trend supports faster translational timelines and reduces the integration burden for end users. Taken together, these shifts create an environment where strategic partnerships, platform interoperability, and demonstrable clinical impact determine long-term success.

Analyzing how tariff-driven supply chain pressures compel localization, supplier diversification, and resilient procurement strategies across the multiomics value chain

The 2025 tariff environment in the United States has introduced tangible considerations for supply chain resilience, procurement strategy, and cost structure within the multiomics ecosystem. Tariffs on laboratory instruments, reagents, or imported components can increase landed costs, prompting manufacturers and buyers to evaluate sourcing alternatives, localize critical production steps, or renegotiate supplier agreements. In response, many organizations are reassessing total cost of ownership for platform investments and prioritizing vendors that demonstrate transparent supply chains and diversified manufacturing footprints.

These policy shifts also amplify the strategic value of regional partnerships and distributed manufacturing models. Firms that can scale localized assembly, consumable production, or reagent fill-and-finish capacities gain a competitive advantage under tariff pressures. Meanwhile, service providers with flexible, regionally distributed laboratories can mitigate exposure by reallocating sample processing to facilities with preferential trade terms or lower import duties.

From a procurement perspective, research institutions and commercial labs are increasingly adopting multi-year contracts, hedging strategies, and inventory management practices to absorb short-term price volatility. At the same time, the need for clear visibility into upstream component sourcing has elevated supplier audits and contractual clauses that address tariff-related liabilities. Ultimately, the policy environment is pushing the sector toward more resilient, transparent, and geographically diversified supply chains that preserve scientific continuity while controlling operational risk.

Comprehensive segmentation insights revealing how technology choices, omic modalities, product types, applications, and end-user needs determine adoption pathways and value creation

Key segmentation insights reveal where technological choices, scientific priorities, and end-user needs intersect to shape adoption pathways and value propositions. Based on Technology, the market encompasses Mass Spectrometry, Microarrays, qPCR, and Sequencing, with Sequencing further segmented into Next Generation Sequencing and Sanger Sequencing; this technological palette determines throughput, sensitivity, and the nature of downstream analytics that researchers can apply. Based on Omics, the field spans Epigenomics, Genomics, Lipidomics, Metabolomics, Proteomics, and Transcriptomics; each omic layer contributes distinct biological context and poses unique analytical challenges related to sample prep, dynamic range, and data integration.

Based on Product Type, offerings include Consumables, Instruments, and Software and Services, with Software and Services further differentiated into Services and Software, and Services subdivided into Data Analysis and Sample Preparation; such product taxonomy underscores the growing importance of bundled solutions that combine hardware with analytical and preparatory services. Based on Application, primary use cases encompass Agriculture and Food Testing, Biomarker Discovery, Clinical Diagnostics, Drug Discovery and Development, and Personalized Medicine; these applications drive differing requirements for regulatory compliance, throughput, and interpretive frameworks. Based on End User, the ecosystem serves Academic and Research Institutes, Contract Research Organizations, Hospitals and Diagnostic Laboratories, and Pharmaceutical and Biotechnology Companies; each end-user segment prioritizes distinct value drivers, from exploratory flexibility to validated, clinically compliant workflows.

Interpreting these segmentations together highlights where investments will matter most: platforms that enable high-quality sample processing, interoperable data pipelines that support multi-omic integration, and services that reduce technical barriers for non-specialist end users. In short, success hinges on aligning technological capabilities with application-specific needs and end-user operational realities.

Actionable regional insights describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence adoption, regulation, and partnership strategies in multiomics

Regional dynamics exert a powerful influence on technology deployment, regulatory alignment, and partnership strategies across the multiomics landscape. In the Americas, research intensity, venture funding, and a robust network of biotech clusters drive rapid adoption of advanced sequencing and mass spectrometry platforms, while a complex patchwork of reimbursement and regulatory frameworks requires targeted validation strategies. Meanwhile, academic-industry collaborations and contract research organizations in the region foster translational pipelines that accelerate proof-of-concept studies and early clinical adoption.

Across Europe, Middle East & Africa, regulatory harmonization efforts, strong public research infrastructures, and growing commercial investment support methodical integration of multiomics into healthcare and agricultural applications. Stakeholders in these markets often prioritize interoperability, data protection, and harmonized performance standards, creating demand for validated workflows and compliant analytics. In Asia-Pacific, rapid infrastructure build-out, manufacturing scale, and government-led science initiatives are expanding local production capacities and driving aggressive adoption of sequencing technologies and automated sample handling systems. The region's diverse regulatory environments and large patient populations also create opportunities for large-scale cohort studies and localized biomarker discovery.

Collectively, these regional characteristics underscore the need for geographically nuanced strategies. Organizations must tailor commercialization, regulatory, and partnership approaches to regional priorities, balancing global platform standardization with local operational flexibility.

Key company insights highlighting how platform integration, validation capabilities, and service differentiation determine competitive advantage across multiomics players

Competitive dynamics in multiomics center on the ability to deliver reliable, validated end-to-end solutions that combine high-performance instruments, reproducible consumables, and scalable analytics. Key companies distinguish themselves through investments in platform interoperability, demonstrated clinical or agricultural utility, and partnerships that extend their value proposition into downstream applications. Strategic M&A and partnership activity continues to align specialized capabilities-such as niche sample preparation chemistry or advanced informatics-with broader platform providers seeking comprehensive offerings.

Market differentiation also arises from service excellence; organizations that provide robust validation support, regulatory documentation, and training resources secure deeper customer relationships. Similarly, firms that offer modular software with open APIs facilitate integration into existing laboratory information management systems and analysis pipelines, lowering barriers for enterprise adoption. Investors and strategic partners increasingly prize companies that demonstrate end-user-focused commercialization strategies, geographic manufacturing resilience, and transparent data governance practices. Ultimately, market leaders combine technical credibility with commercial agility, enabling them to scale adoption across academic, clinical, and industrial customers.

Actionable recommendations for industry leaders to enhance platform interoperability, supply chain resilience, regulatory support, and service-led commercialization strategies

Industry leaders can accelerate value capture by aligning strategic actions with technological and regulatory realities while prioritizing resilience and customer-centricity. First, investing in interoperable platforms and open data standards reduces integration friction and increases the appeal of solutions across end users with heterogeneous infrastructure. Next, expanding localized manufacturing or establishing regional partnerships mitigates tariff and supply chain risks, while offering faster turnaround times for critical consumables and reagents.

Additionally, integrating comprehensive validation packages and regulatory support into product offerings lowers adoption barriers in clinical and diagnostic contexts. Leaders should also develop tiered service models that include sample preparation, data analysis, and clinical interpretation to address the needs of both high-throughput research centers and diagnostic laboratories. To cultivate long-term trust, companies must implement transparent data governance frameworks and robust provenance tracking to satisfy institutional and regulatory auditors. Finally, strengthening cross-disciplinary talent pipelines-combining wet-lab expertise, computational biology, and regulatory affairs-ensures organizations can translate multiomic data into actionable biological and clinical insights. These recommendations form a pragmatic blueprint for organizations seeking to scale responsibly and sustainably.

A rigorous mixed-methods research methodology combining expert primary interviews with systematic secondary evidence synthesis to ensure analytic validity and relevance

The research methodology blends primary and secondary evidence to ensure analytical rigor, reproducibility, and relevance. Primary research included structured interviews with domain experts, laboratory directors, and service providers to capture operational realities, validation practices, and procurement drivers. These qualitative inputs were triangulated with technical literature, peer-reviewed studies, and vendor documentation to verify claims about platform capabilities, assay limitations, and analytical workflows.

Secondary research encompassed a systematic review of scientific publications, regulatory guidance documents, and white papers that illuminate technological trends and application-specific requirements. Data collection prioritized sources that detail assay performance characteristics, sample handling best practices, and interoperability standards. Findings were synthesized using thematic analysis and cross-validation steps to surface consistent patterns and areas of divergence. Throughout the process, attention to provenance, methodological transparency, and source credibility underpinned analytical choices, ensuring that conclusions rest on verifiable evidence and reflect current industry practices.

A conclusive synthesis emphasizing the need for validated workflows, interoperable platforms, and resilient commercialization strategies to realize multiomics impact

In conclusion, multiomics represents a strategic inflection point in life sciences where integrated molecular profiling, advanced instrumentation, and sophisticated analytics converge to enable deeper biological insight and translational impact. The field's maturation depends on aligning technological innovation with robust data governance, standardized workflows, and commercially viable service models that lower barriers to adoption. Policy shifts and trade dynamics have highlighted the importance of supply chain resilience and regional agility, making localization and partnership strategies central to long-term operational continuity.

Looking ahead, organizations that prioritize platform interoperability, end-to-end validation, and customer-focused service offerings will be best positioned to translate multiomic data into clinical and commercial outcomes. Cross-sector collaboration among instrument vendors, software developers, service providers, and end users will accelerate the development of validated workflows and reproducible evidence, thereby expanding the range of practical applications. Ultimately, the pathway to impact lies in coupling scientific rigor with pragmatic commercialization and governance frameworks that foster trust, scalability, and measurable benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiomics Market, by Product Type

  • 8.1. Consumables
  • 8.2. Instruments
  • 8.3. Software and Services
    • 8.3.1. Services
      • 8.3.1.1. Data Analysis
      • 8.3.1.2. Sample Preparation
    • 8.3.2. Software

9. Multiomics Market, by Technology

  • 9.1. Mass Spectrometry
  • 9.2. Microarrays
  • 9.3. qPCR
  • 9.4. Sequencing
    • 9.4.1. Next Generation Sequencing
    • 9.4.2. Sanger Sequencing

10. Multiomics Market, by Application

  • 10.1. Agriculture and Food Testing
  • 10.2. Biomarker Discovery
  • 10.3. Clinical Diagnostics
  • 10.4. Drug Discovery and Development
  • 10.5. Personalized Medicine

11. Multiomics Market, by End User

  • 11.1. Academic and Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals and Diagnostic Laboratories
  • 11.4. Pharmaceutical and Biotechnology Companies

12. Multiomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Multiomics Market

16. China Multiomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Bruker Corporation
  • 17.8. Danaher Corporation
  • 17.9. Illumina, Inc.
  • 17.10. PerkinElmer, Inc.
  • 17.11. QIAGEN N.V.
  • 17.12. Roche Holding AG
  • 17.13. Thermo Fisher Scientific Inc.
  • 17.14. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIOMICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIOMICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIOMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIOMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIOMICS MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIOMICS MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIOMICS MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIOMICS MARKET SIZE, BY AGRICULTURE AND FOOD TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIOMICS MARKET SIZE, BY AGRICULTURE AND FOOD TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIOMICS MARKET SIZE, BY AGRICULTURE AND FOOD TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTIOMICS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIOMICS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MULTIOMICS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTIOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIOMICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTIOMICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIOMICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTIOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTIOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIOMICS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTIOMICS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIOMICS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTIOMICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIOMICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MULTIOMICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MULTIOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MULTIOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. G7 MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. NATO MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)